| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2017 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 20,000 | $89.75 | $1,795,037.00 | -8.1% | |
| Dec 14, 2017 | Elaine J Heron | Director | Sell | 800 | $88.90 | $71,116.00 | -2.0% | |
| Nov 30, 2017 | George Eric Davis65 | EVP, General Counsel | Sell | 1,200 | $85.64 | $102,766.80 | -1.4% | |
| Sep 28, 2017 | Robert Baffi | EVP, Technical Operations | Sell | 18,415 | $92.43 | $1,702,030.50 | -39.0% | |
| Sep 22, 2017 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sale+OE | 3,521 | $95.00 | $334,495.00 | -6.8% | |
| Sep 15, 2017 | Henry J Fuchs | President, Worldwide R& D | Sale+OE | 15,000 | $90.50 | $1,357,500.00 | -9.9% | |
| Sep 15, 2017 | V Bryan Lawlis53 | Director | Sale+OE | 3,750 | $91.26 | $342,225.00 | -19.1% | |
| Jun 23, 2017 | George Eric Davis65 | EVP, General Counsel | Sale+OE | 9,844 | $96.60 | $950,930.40 | -10.5% | |
| Jun 22, 2017 | Brian Mueller64 | SVP, Corporate Controller | Sale+OE | 2,671 | $100.00 | $267,100.00 | -17.2% | |
| Jun 19, 2017 | Henry J Fuchs | President, Worldwide R& D | Sale+OE | 15,000 | $90.00 | $1,350,000.00 | -9.9% |